In the near future, oncologists may be using a finger-size plastic chip with tiny channels to extract a dozen or so cancer cells from a sample of a patient’s blood. Those cells, called circulating tumor cells, could then be screened for genetic disruptions that an oncologist could target with drugs best suited to attacking the tumor.
Commercial Release of 3D (Breast Tomosynthesis) Biopsy Option Strengthens Hologic's Position as Provider of the Nation's Most Comprehensive Portfolio of Interventional Breast Health SolutionsJuly 15, 2013 4:15 pm | by PR Newswire | News | Comments
Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, recently expanded its extensive array of interventional and imaging solutions for breast health with the launch of the world's first 3D breast biopsy option.
Magnetic hyperthermia is viewed as an attractive approach for the treatment of certain cancers as it has no known side effects compared to more conventional therapies such as chemotherapy. It is particularly suitable for the treatment of prostate cancer and brain tumors. However, until now there has been no clear theoretical understanding of how it actually works.
Imagine what could happen when medical and chip experts team up. Would it be possible for chips to revolutionize healthcare in the same way they have revolutionized the electronics industry? Let’s dream: a cheap technology that allows accurate and reliable diagnostics for everyone, at any place and at any time.
A University of Southampton Professor, in collaboration with colleagues at the BC Cancer Agency Research Centre, have discovered a novel way of killing cancer cells. The research, recently published in the journal Cell, has found a new potential treatment for cancer, which leaves the body's healthy cells undamaged.
A new proposal from the Centers for Medicare & Medicaid Services would help level at least 1 battlefield between radiosurgery devices makers Elekta and Varian Medical Systems. The reimbursement proposal would offer equal payment to healthcare providers conducting single-treatment radiosurgery for brain tumors, whether the procedure is conducted with Elekta's Gamma Knife or Varian's Linac.
On this episode of The Pulse, a device that helps train the brain to turn sounds into images, detecting cancer by imaging the consumption of sugar, biomedical applications for a new hydrogel, and a nanofiber mesh that treats tumors with both thermotherapy and chemotherapy.
Chemists from North Carolina State University have performed a DNA-based logic-gate operation within a human cell. The research may pave the way to more complicated computations in live cells, as well as new methods of disease detection and treatment.
While the use of ultrasound to identify tumors during kidney cancer surgery is gaining acceptance, a research team at Henry Ford Hospital has successfully taken it a step further by showing an added benefit when the procedure is done robotically.
Inspired by studies demonstrating canine abilities to sniff out cancerous biomarkers, a team of U.K. researchers developed a scent-analysis device that they say can diagnose early signs of bladder cancer. In a test of nearly 100 urine samples, the device, called OdorReader, was 100% accurate in distinguishing which samples came from cancer patients.
Surefire Infusion System Found Safe and Effective for Delivery of 90Y in Treating Inoperable Liver CancerJuly 10, 2013 6:00 am | by PR Newswire | News | Comments
Case reports published in the Journal of Cardiovascular and Interventional Radiology found that by using the Surefire Infusion System, radioembolization could be successfully performed without the need to protect nearby blood vessels, a significant advance that may enable doctors to safely extend liver cancer treatment to patients who were previously deemed untreatable.
EDP Biotech, the US-based developer of a blood test to detect the early stages of colon cancer called ColoMarker™, today announced its plans to commercialize the product and bring the new technology to market. Unlike other diagnostic tests currently in development, the ColoMarker test detects a level of CA11-19 antigen.
New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic leukemia.
Cell Signaling Technology announced today the issuance of a key US patent, 8,481,279, which relates to methods for inhibiting the progression of lung cancers that express the EML4-ALK fusion gene. The ALK fusion gene is an alteration or defect in a normal gene called anaplastic lymphoma kinase that is thought to play a critical role in the growth of some non-small cell lung cancers
Michael Feiz, M.D., F.A.C.S believes that it's becoming clear that the prevention of cancer is another major benefit of healthy, long-term weight loss that can be fostered by such bariatric procedures as the sleeve gastrectomy and the Lap Band. Obese people are used to hearing warnings regarding heart disease, high blood pressure, diabetes, and stroke; however, the link between obesity and cancer is often left out of the discussion.
A new technique for detecting cancer by imaging the consumption of sugar with magnetic resonance imaging has been unveiled by UCL scientists. The breakthrough could provide a safer and simpler alternative to standard radioactive techniques and enable radiologists to image tumors in greater detail.
CEA-Leti Announces €1 Million from bpifrance to Speed Preclinical Development of Cancer-Detecting NanoparticlesJuly 3, 2013 12:15 pm | by CEA-Leti | News | Comments
CEA-Leti has announced €1 million in funding from bpifrance to accelerate preclinical development of a liver-cancer detection system called LipImage 815. The grant will accelerate the development of LipImage 815, including production and regulatory toxicity evaluation.
A research team headed by Dr. Mitsuhiro Ebara, a MANA Scientist of the Biomaterials Unit of the International Center for Materials Nanoarchitectonics, National Institute for Materials Science, developed a new nanofiber mesh which is capable of simultaneously realizing thermotherapy and chemotherapy of tumors.
One of the greatest pleasures I have as FDA commissioner is the opportunity to meet with so many who are making a real difference in the world of health care, including researchers, doctors, drug industry leaders, foundations, and advocates for patients and families, including most recently the Alexandria Summit for Oncology.
Blaze Biosciences is more than halfway to a targeted $15 million in a Series B round to fund its Tumor Paint, a surgical tool that visually distinguishes solid tumor cells from healthy cells. Founded in 2010, the Seattle, Wash.-based Blaze Biosciences has roped in about $8.1 million since opening the round in June.
To unlock the potential of more frequent therapy, medical devices must move out of the doctor’s office and travel with patients to their homes and offices. But, this great opportunity is not without its challenges. The same patient who stands to reap great benefit from a home medical device may instead endanger themselves by applying the device incorrectly.
Guided Therapeutics and I.T.E.M. Medical Technologies Group Announce Turkish Ministry of Health Sponsored Cervical Cancer Prevention Program Involving the LuViva® Advanced Cervical ScanJuly 2, 2013 8:29 am | by Business Wire | News | Comments
NORCROSS, Ga. & ANKARA, Turkey--(BUSINESS WIRE)--Jul 2, 2013--First graph, second sentence should read: The program for 2013 and 2014, to be funded by Turkey’s Ministry of Health (sted The program for 2013 and 2104). The corrected release reads: GUIDED THERAPEUTICS AND...
VIZZIA Technologies Deploys CenTrak's Clinical-Grade Real-Time Location SystemT (RTLS) to transform the patient experience at Florida Cancer SpecialistsJuly 2, 2013 7:00 am | by The Associated Press | News | Comments
VIZZIA Technologies, a leading provider of process and technology solutions, announced today that its clinical workflow optimization solution was recently installed at Florida Cancer Specialists & Research Institute's (FCS) Tampa Cancer Center location. The newly constructed 35,990 square...
An early-stage company aims to commercialize new optical materials for denser data storage and better cancer treatments.A startup focused on developing novel optical materials received $1 million in first-round funding last month from the venture capital firm Quantum Wave Fund to advance its early-stage technology.
As more therapies are able to indicate implantable devices for treatment, incorporating drug delivery into them can be a significant additional benefit. Even when drug delivery is the primary function, implantable devices can be preferable. This article reviews some representative applications that device designers can leverage in developing new products for the implantable drug delivery market.